On June 1, 2026, Solomon Moshkevich, who serves as President of Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), completed a sale of company common stock. Mr. Moshkevich sold a total of 3,000 shares, representing an aggregate value of $655,294.
The pricing for these transactions varied across the range of $217.5199 to $220.6674 per share. Following the disposition of these shares, Mr. Moshkevich's direct holdings in Natera common stock were adjusted, leaving him with 137,643 shares.
The timing of this insider sale occurs against a backdrop of recent performance data for Natera’s stock. While NTRA has generated a 27% return over the preceding year, the current share price remains at 17% below its peak value recorded over the past 52 weeks, which was $256.36.
From a valuation perspective, some analysis suggests that Natera’s stock currently appears overvalued relative to its Fair Value estimate, placing it among those tracked by certain platforms as being highly valued.
Crucially, the sale of these shares was not impulsive; it was executed under the framework of a Rule 10b5-1 trading plan. Mr. Moshkevich had initially adopted this specific plan on November 26, 2024, which establishes a predefined schedule for transactions.
Beyond the insider activity, Natera Inc. has recently announced several significant developments that highlight its ongoing operational focus and expansion within diagnostic testing fields. The company has made notable enhancements to its Panorama non-invasive prenatal test. This technological upgrade specifically involves new sequencing technology designed to improve performance when analyzing samples that contain low fetal fraction, consequently reducing the no-call rate down to 0.5%.
In the domain of oncology diagnostics, Natera deepened its partnerships. The company collaborated with Diakonos Oncology Corp. to assess molecular response in various melanoma therapy trials. This specific collaboration utilizes Natera’s Signatera test and involves analyzing circulating tumor DNA within patients who are participating in a Phase I/II trial for an investigational therapeutic approach.
Further solidifying its scientific presence, Natera also plans to present 35 oncology abstracts at the upcoming American Society of Clinical Oncology Annual Meeting. These presentations will focus specifically on molecular residual disease testing methods and the application of the Signatera test.
In terms of corporate governance, the board structure received reinforcement with the appointment of Thomas Lynch and Eric Rubin as new directors. Both individuals bring significant expertise in the field of oncology to Natera's leadership team.
Market analysts have also shown renewed interest in the company. Wolfe Research initiated coverage on Natera, assigning an